NAUT
$2.65
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States.
Recent News
Nautilus Biotechnology, Inc. Q4 2025 Earnings Call Summary
Moby summary of Nautilus Biotechnology, Inc.'s Q4 2025 earnings call
Nautilus Biotechnology Q4 Earnings Call Highlights
Nautilus Biotechnology (NASDAQ:NAUT) used its fourth-quarter 2025 earnings call to highlight recent steps toward commercialization of its proteomics platform, alongside continued cost reductions and updated expectations for 2026 spending and revenue. Management said 2025 closed with “tangible progre
Nautilus Biotechnology Inc (NAUT) Q4 2025 Earnings Call Highlights: Strategic Advances and ...
Nautilus Biotechnology Inc (NAUT) reports a significant decrease in operating expenses and unveils promising collaborations, while preparing for increased investment in 2026.
Jefferies Upgrades BETA Technologies, Inc. (BETA) to Buy
BETA Technologies, Inc. (NYSE:BETA) is among the 11 Newly-Listed NYSE Stocks to Buy Now. On February 11, 2026, Jefferies analyst Sheila Kahyaoglu upgraded BETA Technologies, Inc. (NYSE:BETA) to Buy from Hold, previously with a $30 price target. Sheila Kahyaoglu said the shares look compelling at current levels following recent risk-off trading and ahead of several […]
3 Penny Stocks With Market Caps Over $50M To Watch
As February begins, major U.S. stock indexes have surged, with the Dow Jones Industrial Average adding 515 points and the S&P 500 nearing record highs. This optimistic start to the month highlights a market environment where investors are keenly exploring opportunities across various sectors. Though often seen as a relic of past trading days, penny stocks still represent significant growth potential, particularly when they come from smaller or newer companies with strong financial foundations.